Metabolomics and Transcriptomics of Low- and High-Grade Gliomas

Brief summary (registry, in English)

The goal of this observational study is to better define the molecular profile of rare brain tumors (gliomas) based on the levels of their metabolites and transcripts (the intermediate step between DNA information and proteins). The main question it aims to answer is to identify new brain tumour subgroups of clinical relevance that might explain the very different history these patients might follow. Additionally, studies on gliomas require cellular cultures and animal models for the development of new medications, but these models are still scarce and rudimental for many types of gliomas. The second aim of this study is to implement better models for these tumors, for a more effective development of new medications. Patients enrolled in this study will not undergo any additional procedures with respect to those necessary for gold-standard management of these brain tumors. A small sample of the resected tumour will be used for advanced analyses investigating the metabolic and transcriptomic profile and used for temptative establishment of cellular cultures and animal models of these pathologies.

What you commit to

• Study type: Observational
• Planned participants: 220
• From 1 Apr 2026 to the primary completion date, Mar 2029
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.